Literature DB >> 16937286

Reinforcement therapy using nitric oxide synthase inhibitors against endotoxin shock in dogs.

Hiroyasu Suga1, Takao Nakagawa, Yukihiro Soga, Yoshizumi Deguchi, Tadashi Suzuki, Norio Miyoshi, Yoshiaki Imamura, Masaru Fukuda.   

Abstract

PURPOSE: Nitric oxide synthase (NOS) inhibitors were confirmed to correct the hypotension associated with septic shock, but the overall prognosis is often pessimistic. The histological findings failed to show any improvement. In fact, some patients even exhibited signs of exacerbation. The purpose of this study was to investigate the therapeutic effects of NOS inhibitors and catecholamines in dogs suffering from endotoxin shock. The histological changes produced by these agents were also evaluated.
METHODS: Mongrel dogs were used under midazolam anesthesia. A PiCCO continuous cardiac output monitoring catheter was placed in the femoral artery, and a central venous monitoring catheter was placed in the external carotid artery.
RESULTS: Endotoxin (0.5 mg/kg, i.v.) was administered to cause shock. After this shock state was observed, the NOS inhibitors and catecholamines raised the blood pressure, and norepinephrine (NA, 2 microg/kg/h) was found to be more potent than S-methylisothiourea (SMT, 20 microg/kg/h). The combined effects of SMT-NA or SMT-DOB were greater than those of NA or dobutamine (DOB) alone. The histological changes induced by endotoxin shock were not ameliorated by the administration of NOS inhibitors but instead appeared to be exacerbated to some degree.
CONCLUSION: NOS inhibitors combined with cathecholamines were thus suggested to be able to reduce the cathecolamine dosage in patients suffering from septic shock; They are thus considered to be hemodynamically effective agents.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16937286     DOI: 10.1007/s00595-006-3248-z

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  16 in total

1.  Myocardial and circulatory effects of E. coli endotoxin; modification of responses to catecholamines.

Authors:  J R Parratt
Journal:  Br J Pharmacol       Date:  1973-01       Impact factor: 8.739

2.  Evidence of increased nitric oxide production in patients with the sepsis syndrome.

Authors:  T Evans; A Carpenter; H Kinderman; J Cohen
Journal:  Circ Shock       Date:  1993-10

Review 3.  Nitric oxide in sepsis and endotoxaemia.

Authors:  J R Parratt
Journal:  J Antimicrob Chemother       Date:  1998-01       Impact factor: 5.790

Review 4.  Cardiovascular alterations in septic shock.

Authors:  J L Vincent
Journal:  J Antimicrob Chemother       Date:  1998-01       Impact factor: 5.790

5.  A selective inhibitor of inducible in nitric oxide synthase prolongs survival in a rat model of bacterial peritonitis: comparison with two nonselective strategies.

Authors:  J S Aranow; J Zhuang; H Wang; V Larkin; M Smith; M P Fink
Journal:  Shock       Date:  1996-02       Impact factor: 3.454

6.  Role of tissue factor in disseminated intravascular coagulation.

Authors:  H Asakura; Y Kamikubo; A Goto; Y Shiratori; M Yamazaki; H Jokaji; M Saito; C Uotani; I Kumabashiri; E Morishita
Journal:  Thromb Res       Date:  1995-11-01       Impact factor: 3.944

7.  Nitric oxide causes hyporeactivity to phenylephrine in isolated perfused livers from endotoxin-treated rats.

Authors:  C M Pastor; T R Billiar
Journal:  Am J Physiol       Date:  1995-01

Review 8.  Myocardial function in sepsis and endotoxin shock.

Authors:  F L Abel
Journal:  Am J Physiol       Date:  1989-12

9.  Beneficial effects and improved survival in rodent models of septic shock with S-methylisothiourea sulfate, a potent and selective inhibitor of inducible nitric oxide synthase.

Authors:  C Szabó; G J Southan; C Thiemermann
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-20       Impact factor: 11.205

10.  Stimulation of the nitric oxide synthase pathway in human hepatocytes by cytokines and endotoxin.

Authors:  A K Nussler; M Di Silvio; T R Billiar; R A Hoffman; D A Geller; R Selby; J Madariaga; R L Simmons
Journal:  J Exp Med       Date:  1992-07-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.